Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Silvina Gallo
Roberto A. Calle
Steven G. Terra
Annpey Pong
Lisa Tarasenko
Annaswamy Raji
10.6084/m9.figshare.12481244.v1
https://adisjournals.figshare.com/articles/figure/Effects_of_Ertugliflozin_on_Liver_Enzymes_in_Patients_with_Type_2_Diabetes_A_Post-Hoc_Pooled_Analysis_of_Phase_3_Trials/12481244
<p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020.<b> </b></p>
2020-06-29 09:57:34
Alanine aminotransferase
Aspartate aminotransferase
Body weight
Ertugliflozin
Fibrosis-4 index
HbA1c
Liver enzymes
SGLT2 inhibitor
Type 2 diabetes mellitus